急诊低血压患者推注去氧肾上腺素的安全性
本研究对42个月内急诊科使用预充式注射器推注去氧肾上腺素(BDPE)的181例低血压患者进行结构化病历回顾,其中147例有完整用药前后生命体征。不良事件定义为给药后30分钟内收缩压>180 mmHg、舒张压>110 mmHg或心率<50次/分,严重不良事件定义为需药物干预纠正生命体征异常的不良事件。结果发现5例不良事件、无严重不良事件:3例收缩压>180 mmHg但无显见伤害,无患者舒张压>110 mmHg,2例出现心动过缓但平均动脉压仍改善。作者认为BDPE似乎不引起需干预的反射性心动过缓或高血压,但需前瞻性试验证实其安全性。
要点
- 在急诊低血压患者中,181例使用BDPE,147例有完整用药前后生命体征,仅5例不良事件、0例严重不良事件。
- 3例患者用药后30分钟内收缩压>180 mmHg,但原文报告无显见伤害;无患者舒张压>110 mmHg。
- 2例患者用药后出现心动过缓(心率<50次/分),但两例平均动脉压均改善。
- 作者结论认为BDPE似乎不引起需干预的反射性心动过缓或高血压,但需前瞻性试验证实。
适用人群与场景
- 急诊科低血压患者,使用预充式注射器推注去氧肾上腺素(BDPE)。
诊断标准与关键阈值
- 不良事件定义:给药后30分钟内收缩压>180 mmHg、舒张压>110 mmHg或心率<50次/分。
- 严重不良事件定义:不良事件中需药物干预纠正生命体征异常。
研究设计与关键结果
- 研究类型:结构化病历回顾;样本量:42个月内共181例急诊使用BDPE,其中147例有完整用药前后生命体征。
- 主要结果:5例不良事件,0例严重不良事件;3例收缩压>180 mmHg,无患者舒张压>110 mmHg,2例心动过缓但平均动脉压改善。
- 作者假设BDPE是急诊低血压患者安全的短期升压选择。
证据类型、等级与局限
- 证据类型:结构化病历回顾。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为BDPE似乎不引起需干预的反射性心动过缓或高血压,但需前瞻性试验证实其安全性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Bolus-dose phenylephrine (BDPE) is routinely used to treat hypotension in the operating room. BDPE's fast onset of action and ability to be administered peripherally have prompted calls for its use in the Emergency Department (ED). There are few published data on the safety of BDPE use in the ED. Primary concerns include BDPE's potential to cause dangerous hypertension or reflex bradycardia. We hypothesize that BDPE is a safe short-term vasopressor choice for hypotensive ED patients.
METHODS: We conducted a structured chart review for all patients who received BDPE from preloaded syringes over 42months. We defined an adverse event (AE) as sBP>180, dBP>110, or HR<50 within 30min of receiving BDPE. We defined a serious adverse event (SAE) as an AE with pharmacologic intervention to correct vital sign abnormality. We also compared mean arterial pressure (MAP), sBP, and dBP pre/post BDPE administration to assess effectiveness. We used a two-sample t-test to assess for differences between the mean delta MAP after low versus high-dose BDPE.
RESULTS: We identified 181 cases of ED use. 147 cases had complete pre/post vital signs. We identified 5 AEs and no SAEs. Three patients developed sBP>180mmHg. The patients suffered no apparent harm. No patients had dBP>110. Two patients developed bradycardia post-drug. In both cases, MAP improved despite bradycardia.
CONCLUSIONS: BDPE does not appear to cause reflex bradycardia or hypertension requiring intervention among hypotensive ED patients. The apparent safety of BDPE should be confirmed in prospective trials.
参考来源
- Swenson K, Rankin S, Daconti L, et al. Safety of bolus-dose phenylephrine for hypotensive emergency department patients. Am J Emerg Med. 2018. PMID: 29472039. doi:10.1016/j.ajem.2018.01.095
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。